|
Market Closed -
Nasdaq
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 10.62 USD | +3.51% |
|
+0.95% | +72.68% |
| 13/10 | ImmuCell Q3 Preliminary Sales Rise | MT |
| 13/10 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 9.32Cr | - | - | - | - | - |
| 1,14300Cr | |||||
| 65TCr | |||||
| 51TCr | |||||
| 38TCr | |||||
| 35TCr |
- Stock Market
- Stocks
- ICCC Stock
- Charts ImmuCell Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
